Regulus Therapeutics Inc (RGLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) has a cash flow conversion efficiency ratio of -0.154x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.61 Million) by net assets ($69.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Regulus Therapeutics Inc (RGLS) net asset quality to measure how much of total assets are equity-financed.
Regulus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Regulus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RGLS capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Regulus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regulus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yunnan Coal & Energy Co Ltd
SHG:600792
|
0.091x |
|
Fujian Rongji Software Co Ltd
SHE:002474
|
-0.005x |
|
Idaho Strategic Resources Inc
NYSE MKT:IDR
|
0.031x |
|
Saimo Electric Co Ltd
SHE:300466
|
-0.014x |
|
Anhui Genuine New Materials Co Ltd
SHG:603429
|
-0.040x |
|
Changzhou Kaidi Electrical Inc
SHG:605288
|
-0.019x |
|
Msscorps Co Ltd
TW:6830
|
0.071x |
|
ForFarmers NV
AS:FFARM
|
0.194x |
Annual Cash Flow Conversion Efficiency for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Regulus Therapeutics Inc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Regulus Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.41 Million | $-41.67 Million | -0.545x | +56.83% |
| 2023-12-31 | $21.19 Million | $-26.77 Million | -1.263x | -64.77% |
| 2022-12-31 | $33.29 Million | $-25.53 Million | -0.767x | -74.65% |
| 2021-12-31 | $54.96 Million | $-24.13 Million | -0.439x | +8.85% |
| 2020-12-31 | $26.03 Million | $-12.54 Million | -0.482x | +51.36% |
| 2019-12-31 | $20.02 Million | $-19.82 Million | -0.990x | -113.40% |
| 2018-12-31 | $-5.85 Million | $-43.27 Million | 7.392x | +542.92% |
| 2017-12-31 | $35.22 Million | $-58.77 Million | -1.669x | -64.53% |
| 2016-12-31 | $56.08 Million | $-56.88 Million | -1.014x | -152.44% |
| 2015-12-31 | $124.08 Million | $-49.86 Million | -0.402x | -34.26% |
| 2014-12-31 | $132.01 Million | $-39.51 Million | -0.299x | +1.27% |
| 2013-12-31 | $93.46 Million | $-28.33 Million | -0.303x | -115.83% |
| 2012-12-31 | $62.09 Million | $-8.72 Million | -0.140x | -138.69% |
| 2011-12-31 | $-41.49 Million | $-15.06 Million | 0.363x | -76.41% |
| 2010-12-31 | $8.00 Million | $12.31 Million | 1.539x | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more